Healing & Repair
GHK-Cu (Copper Tripeptide-1)
← Back to Library
Site-only / unverified FDA safety flag Site-only / unverified Repair Longevity
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 50, 100 mg
Dosing window: Anytime
Receptor / target: MMP; DNA Repair
Properties: Not stated
Pre-mixed: No
Site-sourced protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 1mg 1x Daily | 5 Days on, 2 Days Off. Rotate injection sites frequently due to bruising. |
| Weeks 5-8 | 1.5mg 1x Daily | 5 Days on, 2 Days Off. Rotate injection sites frequently due to bruising. |
| Weeks 9-12+ | 2mg 1x Daily | 5 Days on, 2 Days Off. Rotate injection sites frequently due to bruising. |
Site-provided protocol; not independently verified as label dosing unless graded otherwise on this page.
Alternative 1: The BPC Blend Buffer
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 1.5mg GHK-Cu + 250mcg BPC-157 | Pulling BPC-157 into the same syringe as GHK-Cu acts as a buffer, almost entirely eliminating the severe injection site sting. |
Site-provided alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative 2: 8-Week Daily Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 1mg 1x/day | 7 days/week. |
Site-provided alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Repair protocols depend on injury type, timing, loading, inflammation, and angiogenesis risk. Rodent or cell data can suggest a mechanism, but it does not prove a human dose or replace rehab and diagnosis. Entry context: target (MMP; DNA Repair); route Subcutaneous; timing Anytime. Site-only/low dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. The copper fear is usually overstated, but not imaginary. GHK-Cu is not pure copper; 4 mg is roughly under 1 mg elemental copper, while the adult oral copper UL is 10 mg/day from food and supplements. Injection route, baseline copper status, Wilson's disease, liver disease, and total dietary/supplement copper still matter. Do not add zinc reflexively; excess zinc can lower copper status and should be based on labs or clinician guidance.
Independent evidence
Independent safety notes: FDA lists injectable GHK-Cu among withdrawn nominated bulk substances with limited human safety data. Copper toxicity concerns should be framed around total elemental copper, route, and copper-handling disorders; reflex zinc supplementation is not supported and excess zinc can reduce copper status.
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No independently verified storage guidance found. Treat any site-sourced storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (site-sourced)
- Wilson's disease or other genetic copper metabolism disorders: the copper component of GHK-Cu bypasses normal hepatic copper regulation; copper accumulation in subjects with impaired copper transport (ATP7B mutations) is a serious risk. Site-only / unverified
- Known copper hypersensitivity or copper allergy: systemic injection of a copper complex in a hypersensitive subject may provoke significant immune reactions. Site-only / unverified
- Active malignancy: GHK-Cu promotes angiogenesis via VEGF/VEGFR2 upregulation; while preclinical data suggests anti-metastatic gene regulation, the pro-angiogenic mechanism remains a contraindication in subjects with active tumors. Site-only / unverified
- Pregnancy: no human safety data; copper homeostasis is tightly regulated during fetal development; avoid. Site-only / unverified
- Breastfeeding: no established safety data. Site-only / unverified
- Known hypersensitivity to GHK-Cu or peptide excipients. Site-only / unverified
- Copper-chelating drugs (for example penicillamine or trientine) and pharmacologic zinc used specifically to lower copper may interfere with the active copper complex. Do not add zinc simply to 'balance' GHK-Cu; high-dose zinc can lower copper status and should be based on labs or clinician guidance. Source-supported caution
- Hemochromatosis or iron overload disorders: impaired metal metabolism may affect copper handling. Site-only / unverified
- Individuals with elevated baseline serum copper levels: risk of copper toxicity at systemic injectable doses. Site-only / unverified
Side effects (site-sourced)
- Severe Post-Injection Pain (PIP): the defining adverse effect of subcutaneous GHK-Cu; caused by the copper ion reacting with subcutaneous tissue; characterized by burning, stinging, redness, and welts at the injection site; intensity varies by concentration, volume, and injection location; nearly eliminated by co-injecting with BPC-157. Site-only / unverified
- Bruising and hematoma formation at injection sites: particularly with daily protocols; mandatory site rotation mitigates this but does not eliminate it. Site-only / unverified
- Local redness and induration: tissue response to copper deposition; resolves between injection sessions; the 5-on/2-off schedule provides recovery time. Site-only / unverified
- Copper toxicity fear check: adult oral copper UL is 10 mg/day from food and supplements, and GHK-Cu is not pure copper (4 mg is roughly under 1 mg elemental copper). That does not make injection risk zero: route, total copper exposure, liver disease, Wilson's disease, elevated baseline copper, and chronic high-dose use still matter. Source-supported caution
- "Copper uglies": a rare paradoxical effect where excessive MMP-1 stimulation at high concentrations causes collagen fragmentation rather than synthesis, resulting in apparent skin quality degradation; primarily documented anecdotally in topical overuse; not formally documented at injectable doses. Site-only / unverified
- Mild systemic fatigue: occasionally reported in first 1-2 weeks of use; likely related to initial tissue remodeling signal load. Site-only / unverified
- Headache: uncommon; possibly related to VEGF-mediated vasodilation. Site-only / unverified
- Temporary melanin increase at injection sites: tyrosinase activation from copper delivery can produce local hyperpigmentation; resolves over weeks after cessation. Site-only / unverified
- Nausea: rare; may be copper-related at higher doses. Site-only / unverified
- Potential MMP overactivation at supraphysiological concentrations: theoretical; context-dependent MMP regulation can shift from constructive to destructive at excessive doses. Site-only / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
Sources
- https://the source dataset.com/peptide-codex.php
- https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
- https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks?pg=3
- https://ods.od.nih.gov/factsheets/Copper-HealthProfessional/
- https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/